CA-INVESTCLOUD
7.2.2024 15:01:28 CET | Business Wire | Press release
InvestCloud, a global provider of wealth and asset management solutions, today announced the appointment of Shawn Donovan as Chief Revenue Officer (“CRO”), responsible for the company’s sales and account management strategy globally with a key focus on enhancing value creation and delivery for clients. This announcement further underscores InvestCloud’s commitment to leading the digital transformation of wealth, strengthening the client experience and accelerating growth, as the company supports more than $6 trillion in assets under management across its platforms.
Mr. Donovan brings extensive experience in the financial services and technology industry to his new role at InvestCloud. He spent more than 30 years in progressive global leadership roles with responsibilities spanning sales and account management, strategy and operations, and general management, while at EDS, Acxiom, Fiserv and Neustar. In addition to serving on various executive management committees and leading large-scale global sales organizations throughout his career, Mr. Donovan’s background includes over five years as the Chief Sales Officer at Fiserv, where he managed teams with more than 400 sales executives and achieved record-setting sales.
“For more than three decades, Shawn has been leading sales and operational teams serving the financial services industry with a focus on driving outstanding sales and revenue growth,” said Jeff Yabuki, Chairman and CEO, InvestCloud. "We are thrilled to welcome Shawn to InvestCloud where we can utilize his deep expertise in building high-performing teams and enhance the value we deliver for our clients and partners.”
Mr. Donovan specializes in business transformation to drive profitable revenue growth and is deeply committed to cultivating talent, developing best-in-class process and achieving consistent strong performance. He has a proven track record in building sales teams and models that deliver results.
“InvestCloud brings a suite of modern, enabling technology solutions to complement the more than $80 trillion in assets expected to pass between generations over the next decade, which we believe will address the changing expectations of a new generation of clients,” said Shawn Donovan. “I’m excited about the tremendous transformation opportunity before us and look forward to working with the team to drive this next generation of growth.”
Prior to Fiserv, Mr. Donovan was Chief Sales Officer at Acxiom, where he led a global sales organization of more than 375 professionals responsible for the expansion of the sales and ongoing support of the Acxiom portfolio of products and services. From Fiserv, Mr. Donovan went on to lead the global sales organization of more than 300 professionals at Neustar, where he was responsible for sales, ongoing support and strategic expansion of the company’s portfolio of products and services.
About InvestCloud
InvestCloud is the global software leader in digital transformation for the wealth management industry, and the US leader for personalization and scale across Advisory programs including unified managed accounts (UMA) and separately managed accounts (SMA). InvestCloud today supports over $6 trillion of assets with over 550 direct clients, including banks and wealth managers, private banks, and asset managers. The company offers digital client and advisor experiences and tools that enable the development of front office wealth management solutions, and UMA/SMA portfolio management, trade execution, accounting, model management and performance investment solutions, resulting in best-in-class experiences and operations for the wealth and asset management industry. Headquartered in Los Angeles, InvestCloud has offices around the world including the United States, Canada, United Kingdom, Switzerland, Italy, Singapore, India, Japan, and Australia.
More information on InvestCloud can be found at www.investcloud.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207814144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
